Table 1 Prognostic indicators of achievement of HIV-1 RNA < 50 copies/mL at week 48.
Raltegravir Group (A) | Efavirenz Group (B) | Difference (A-B) | |||
|---|---|---|---|---|---|
n/N | Response rate | n/N | Response rate | ||
Overall | 241/263 | 91.6% (87.6-94.7) | 230/258 | 89.1 (84.7- 92.7) | 2.5% (-2.6 - 7.7) |
Baseline Plasma HIV-1 RNA (copies/mL) | |||||
≤ 100000 | 111/120 | 92.5%(86.2 - 96.5) | 114/128 | 89.1%(82.3- 93.9) | 3.4% (-4.1 - 11) |
> 100000 | 130/143 | 90.9% (85 - 95.1) | 116/130 | 89.2%(82.6 - 94) | 1.7% (-5.6 - 9.2) |
Baseline CD4 count cells/μL | |||||
≤ 50 | 21/25 | 84% (63.9 - 95.5) | 24/28 | 85.7%(67.3- 96.0) | -1.7% (-23.0 - 18.7) |
> 50 ≤ 200 | 85/95 | 89.5%(81.5 - 94.8) | 83/97 | 85.6%(77.0- 91.9) | 3.9% (-5.7 - 13.7) |
> 200 | 135/143 | 94.4%(89.3 - 97.6) | 122/132 | 92.4%(86.5- 96.3) | 2.0 (-4.1 - 8.5) |
Unknown | 0 | NA | 1/1 | 100% (2.5 - 100) | NA |
HIV-1 Subtype | |||||
Clade B | 186/206 | 90.3%(85.4 - 94.0) | 185/209 | 88.5% (83.4 92.5) | 1.8% (-4.3 7.9) |
Clade Non-B | 52/54 | 96.3%(87.3 - 99.5) | 40/44 | 90.9%(78.3- 97.5) | 5.4% (-4.9 - 18.0) |
Unknown | 3/3 | 100.0%(29.2-100.0) | 5/5 | 100.0%(47.8-100.0) | 0.0% (-59.4 - 46.8) |